Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Similar articles for PubMed (Select 23083346)

1.

CD22 and autoimmune disease.

Dörner T, Shock A, Smith KG.

Int Rev Immunol. 2012 Oct;31(5):363-78. doi: 10.3109/08830185.2012.709890. Review.

PMID:
23083346
2.

CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.

Sieger N, Fleischer SJ, Mei HE, Reiter K, Shock A, Burmester GR, Daridon C, Dörner T.

Arthritis Rheum. 2013 Mar;65(3):770-9. doi: 10.1002/art.37818.

PMID:
23233360
3.

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.

Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang CH.

Blood. 2013 Oct 24;122(17):3020-9. doi: 10.1182/blood-2012-12-473744. Epub 2013 Jul 2.

4.

Epratuzumab for systemic lupus erythematosus.

Wallace DJ, Goldenberg DM.

Lupus. 2013 Apr;22(4):400-5. doi: 10.1177/0961203312469692. Review.

PMID:
23553783
5.

A novel epitope from CD22 regulates Th1 and Th17 cell function in systemic lupus erythematosus.

Yuan J, Yu M, Cao AL, Chen X, Zhang LH, Song Y, Cheng X, Zhou ZH, Wang M, Guo HP, Du R, Liao YH.

PLoS One. 2013 May 21;8(5):e64572. doi: 10.1371/journal.pone.0064572. Print 2013.

6.

ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.

Grewal PK, Boton M, Ramirez K, Collins BE, Saito A, Green RS, Ohtsubo K, Chui D, Marth JD.

Mol Cell Biol. 2006 Jul;26(13):4970-81.

7.

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

Daridon C, Blassfeld D, Reiter K, Mei HE, Giesecke C, Goldenberg DM, Hansen A, Hostmann A, Frölich D, Dörner T.

Arthritis Res Ther. 2010;12(6):R204. doi: 10.1186/ar3179. Epub 2010 Nov 4.

8.

Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.

Rao V, Gordon C.

Immunotherapy. 2014;6(11):1165-75. doi: 10.2217/imt.14.80. Review.

PMID:
25496332
9.

Treatment of systemic lupus erythematosus with epratuzumab.

Traczewski P, Rudnicka L.

Br J Clin Pharmacol. 2011 Feb;71(2):175-82. doi: 10.1111/j.1365-2125.2010.03767.x. Review.

10.

Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model.

Wöhner M, Born S, Nitschke L.

Eur J Immunol. 2012 Nov;42(11):3009-18. doi: 10.1002/eji.201242629. Epub 2012 Oct 17.

PMID:
22965838
11.

CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.

Nitschke L.

Glycobiology. 2014 Sep;24(9):807-17. doi: 10.1093/glycob/cwu066. Epub 2014 Jul 6. Review.

12.

Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.

Rossi EA, Chang CH, Goldenberg DM.

PLoS One. 2014 May 19;9(5):e98315. doi: 10.1371/journal.pone.0098315. eCollection 2014.

13.

Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis.

Odaka M, Hasegawa M, Hamaguchi Y, Ishiura N, Kumada S, Matsushita T, Komura K, Sato S, Takehara K, Fujimoto M.

Clin Exp Immunol. 2010 Feb;159(2):176-84. doi: 10.1111/j.1365-2249.2009.04059.x. Epub 2009 Nov 16.

14.

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR.

Arthritis Res Ther. 2006;8(3):R74. Epub 2006 Apr 21. Erratum in: Arthritis Res Ther. 2008;10(5):406.

15.

Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection.

Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby KL, Clark EA, Goodnow CC.

Immunity. 1998 Apr;8(4):497-508.

16.

CD22 regulates adaptive and innate immune responses of B cells.

Kawasaki N, Rademacher C, Paulson JC.

J Innate Immun. 2011;3(4):411-9. doi: 10.1159/000322375. Epub 2010 Dec 17.

17.

The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease.

Müller J, Nitschke L.

Nat Rev Rheumatol. 2014 Jul;10(7):422-8. doi: 10.1038/nrrheum.2014.54. Epub 2014 Apr 29. Review.

PMID:
24763061
18.

Novel binding site for Src homology 2-containing protein-tyrosine phosphatase-1 in CD22 activated by B lymphocyte stimulation with antigen.

Zhu C, Sato M, Yanagisawa T, Fujimoto M, Adachi T, Tsubata T.

J Biol Chem. 2008 Jan 18;283(3):1653-9. Epub 2007 Nov 15. Erratum in: J Biol Chem. 2008 Feb 29;283(9):5972. Adachi, Takahiro [added].

19.

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.

Tedder TF, Poe JC, Haas KM.

Adv Immunol. 2005;88:1-50. Review.

PMID:
16227086
20.

CD22: an inhibitory enigma.

Walker JA, Smith KG.

Immunology. 2008 Mar;123(3):314-25. Epub 2007 Dec 7. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk